Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vicore Pharma Holding AB ( (SE:VICO) ) just unveiled an update.
Vicore Pharma Holding AB will showcase its clinical-stage portfolio of angiotensin II type 2 receptor agonists at two upcoming healthcare investor conferences in Stockholm and New York, underscoring growing capital-market interest in novel treatments for respiratory and fibrotic diseases. The company plans formal presentations and one-on-one meetings at the DNB Carnegie Healthcare Conference on March 12 and the 10th Annual Nordic-American Healthcare Conference on March 25, moves that are likely aimed at strengthening investor engagement around its lead idiopathic pulmonary fibrosis program and broader ATRAG platform.
The most recent analyst rating on (SE:VICO) stock is a Sell with a SEK9.50 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company focused on developing a new class of angiotensin II type 2 receptor agonists (ATRAGs) with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis. Its lead candidate, buloxibutid, an oral small molecule ATRAG, holds Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and is in a global 52-week Phase 2b ASPIRE trial in idiopathic pulmonary fibrosis.
YTD Price Performance: -13.45%
Average Trading Volume: 637,322
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.75B
See more data about VICO stock on TipRanks’ Stock Analysis page.